Prosecution Insights
Last updated: May 29, 2026

Glycom A/S

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
5
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (40%)
1
Easy (20%)
2
Unknown (40%)

Rejection Statute Mix

BucketCases
§103 only2 (40%)
§112 only1 (20%)
No statute on record2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WHITE, ASHLEY TAYLOR 1 38.5% +80.0%
LEWIS, PATRICK T 1 74.3% +14.5%
CRAIGO, BAHAR ALAWI 1 46.9% +27.0%
KOROTCHKINA, LIOUBOV G 1 28.0% +59.9%
NOBLE, MARCIA STEPHENS 1 67.0% +40.2%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17754400 SEPARATION OF NEUTRAL OLIGOSACCHARIDES FROM FERMENTATION BROTH KOROTCHKINA, LIOUBOV G 8d overdue

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18082793 SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS CRAIGO, BAHAR ALAWI 150d overdue
18257986 BIOMASS REMOVAL BY CENTRIFUGATION LEWIS, PATRICK T 124d overdue
17754400 SEPARATION OF NEUTRAL OLIGOSACCHARIDES FROM FERMENTATION BROTH KOROTCHKINA, LIOUBOV G 8d overdue
17596781 NUCLEIC ACID CONSTRUCT COMPRISING 5' UTR STEM-LOOP FOR IN VITRO AND IN VIVO GENE EXPRESSION NOBLE, MARCIA STEPHENS 14d
18262099 NEW MAJOR FACILITATOR SUPERFAMILY (MFS) PROTEIN (FRED) IN PRODUCTION OF SIALYLATED HMOS WHITE, ASHLEY TAYLOR 15d

Top Art Units

Art UnitApps
1653 2
1691 1
1699 1
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18262099 NEW MAJOR FACILITATOR SUPERFAMILY (MFS) PROTEIN (FRED) IN PRODUCTION OF SIALYLATED HMOS WHITE, ASHLEY TAYLOR 1653 Other Non-Final OA 15d Pending Jul 19, 2023
18257986 BIOMASS REMOVAL BY CENTRIFUGATION LEWIS, PATRICK T 1691 §103 Non-Final OA 124d overdue Pending Jun 16, 2023
18082793 SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS CRAIGO, BAHAR ALAWI 1699 Other Non-Final OA 150d overdue Pending Dec 16, 2022
17754400 SEPARATION OF NEUTRAL OLIGOSACCHARIDES FROM FERMENTATION BROTH KOROTCHKINA, LIOUBOV G 1653 §103 Non-Final OA 8d overdue Pending Mar 31, 2022
17596781 NUCLEIC ACID CONSTRUCT COMPRISING 5' UTR STEM-LOOP FOR IN VITRO AND IN VIVO GENE EXPRESSION NOBLE, MARCIA STEPHENS 1632 §112 Non-Final OA 14d Pending Dec 17, 2021

Managing Glycom A/S's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month